Company: IOBT
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0000950170-25-058699
Chunk: 38

Company: IO Biotech, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 38
---
, a merger. Prior to Keryx, Ms. Sullivan served as head of corporate communications and investor relations at AMAG Pharmaceuticals, Inc., Idenix Pharmaceuticals, Inc., and Genencor International, B.V. Earlier in her career, Ms. Sullivan served in roles of increasing responsibility in both agencies and Fortune 500 companies. Ms. Sullivan has her bachelor of science degree in business from Salem State University and her masters of business administration from Bentley University. Devin W. Smith – Mr. Smith joined the Company in January 2023. Prior to joining the Company, he had served as Senior Vice President and General Counsel of Yumanity Therapeutics, Inc., a biotech company, beginning in June 2021. At Yumanity, he helped lead the sale of the Yumanity’s neuroscience assets to Johnson & Johnson and a reverse merger with a privately held oncology immunotherapy company. Prior to his role at Yumanity, Mr. Smith served as Senior Vice President and General Counsel of Minerva Neurosciences, Inc., from August 2018 to June 2021, where he was responsible for all legal, governance and compliance matters. Before joining Minerva, Mr. Smith served as General Counsel of Stallergenes Greer plc, a publicly traded global biopharmaceutical company focused on allergy immunotherapy products. Previously, Mr. Smith led the North American legal department for EMD Serono, Inc., the biopharmaceutical division of Merck KGaA. Mr. Smith received his J.D. from Suffolk University Law School and his bachelor’s degree from the University of North Carolina – Chapel Hill.

<div align='center'>29</div>

SECURITY OWNERSHIP OF CERTAIN BEN EFICIAL OWNERS AND MANAGEMENT The following table sets forth information relating to the beneficial ownership of our common stock as of April 11, 2025, by: • each person, or group of affiliated persons, known by us to beneficially own more than five percent (5%) of our outstanding shares of common stock; • each of our directors; • each of our named executive officers; and • all our current directors and executive officers as a group. The number of shares beneficially owned by each entity, person, director or executive officer is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment power as well as any shares